TargetFatty-acid amide hydrolase 1 [30-579](Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 4.70nMAssay Description:Inhibition of rat FAAH preincubated for 20 minsMore data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
TargetFatty-acid amide hydrolase 1 [30-579](Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.35nMAssay Description:Inhibition of rat FAAH preincubated for 10 minsMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
TargetFatty-acid amide hydrolase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.02nMAssay Description:Inhibition of human FAAH preincubated for 10 minsMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
TargetFatty-acid amide hydrolase 1 [30-579](Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.20nMAssay Description:Inhibition of rat FAAH preincubated for 20 minsMore data for this Ligand-Target Pair
TargetFatty-acid amide hydrolase 1 [30-579](Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of rat FAAH preincubated for 10 minsMore data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
TargetFatty-acid amide hydrolase 1 [30-579](Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 8.70nMAssay Description:Inhibition of rat FAAH preincubated for 10 minsMore data for this Ligand-Target Pair